Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetics Hypertension Clear all

Conditions: Diabetes, Hypercholesterolaemia, Hypertension, Obesity Type 2 Diabetes Mellitus, Obesity & Overweight, Heart Failure, CAD - Coronary Artery Disease, Stroke Risk, Cardiac Arrythmias, Genetics Hypertension, Genetics, Pharmacogenomics, Pharmacogenomic Testing for Medication Management, Cancer Genetics
Interventions: Color Genomics Genetic Testing Panels; Genetic
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Arteriosclerosis, Hypertension, Heart Diseases
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 64 Years
Timeline: Started 1995
U.S. locations: 3
States / cities: Rochester, Minnesota • Jackson, Mississippi • Rio Grande City, Texas

Conditions: Hypertension, Colon Cancer
Interventions: MINT, Patient Navigation; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older · Male only
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pulmonary Hypertension
Interventions: Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: MRI, Transthoracic Echocardiography, tonometry, EKG; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Osilodrostat (Isturisa); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Diabetes, Stroke, Obesity
Interventions: Not listed
Lead sponsor: Children's & Women's Health Centre of British Columbia; Other
Eligibility: Not listed
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • Louisville, Kentucky • Camden, New Jersey + 1 more

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions: Cannabis, Medical, RYAH-Medtech Inhaler; Drug · Device
Lead sponsor: OMNI Medical Services, LLC; Network
Eligibility: 7 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions: Chlorthalidone, Lisinopril, Amlodipine, Doxazosin; Drug
Lead sponsor: Donna Arnett, 257-5678; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypertension
Interventions: Geneticure Panel for HTN therapy, JNC-8; Drug
Lead sponsor: Geneticure, LLC; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 15
States / cities: Andover, Minnesota • Blaine, Minnesota • Bloomington, Minnesota + 12 more

Conditions: Apparent Mineralocorticoid Excess Syndrome
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Hypertension
Interventions: Induced Stress, Buccal Swab; Behavioral · Procedure
Lead sponsor: Augusta University; Other
Eligibility: 15 Years to 19 Years
Enrollment: 1,099 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Cardiovascular Phenotype, Metabolic Phenotype, Hypertensive Disease, Psychological Phenotype, Audio
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Diseases, Hypertension, Pulmonary
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: Up to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hemianopia, Hemianopsia, Peripheral Visual Field Defect, Blindness, Retinitis Pigmentosa, Glaucoma
Interventions: Collision warning device; Device
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 7 Years to 70 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Chronic Kidney Disease, Genomics
Interventions: Immediate Genetic Testing; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2,052 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Hypertension
Interventions: Metoprolol, Chlorthalidone; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: pravastatin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 22 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

The Effect of Providing Genetic Risk Information on Lifestyle Behaviors in African Americans

Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)

Community-based Approaches to Treating Hypertension and Colon Cancer Prevention

Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

Cardiovascular Complications of Sickle Cell Disease

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Testing the Developmental Origins Hypothesis

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Outcomes Mandate National Integration With Cannabis as Medicine

Genetics of Hypertension Associated Treatments (GenHAT)

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

Natural History of Apparent Mineralocorticoid Excess Syndrome

Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure

Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

Collision Warning Device for Blind and Visually Impaired

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Genetic Testing to Understand and Address Renal Disease Disparities

Pharmacogenomic Evaluation of Antihypertensive Responses 2

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)